CN109091462A - A kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea - Google Patents
A kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea Download PDFInfo
- Publication number
- CN109091462A CN109091462A CN201811078651.7A CN201811078651A CN109091462A CN 109091462 A CN109091462 A CN 109091462A CN 201811078651 A CN201811078651 A CN 201811078651A CN 109091462 A CN109091462 A CN 109091462A
- Authority
- CN
- China
- Prior art keywords
- scutelloside
- agent
- aluminium
- dry suspensoid
- active constituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea, and the scutelloside aluminium dry suspensoid agent of the treatment grice diarrhoea is in terms of mass fraction including following components: active constituent: 510~550 parts；Filler: 435~485 parts；Suspending agent: 5~15 parts；Wherein, the active constituent is scutelloside and the scutelloside aluminum complex that aluminium salt is prepared into.The present invention reacts prepared scutelloside aluminum complex using scutelloside raw material with aluminium salt as active constituent, scutelloside aluminium dry suspensoid agent is prepared by mixing into filler and suspending agent, improve the purity of scutelloside aluminum complex in the dry suspensoid agent, dosage of scutelloside aluminium dry suspensoid agent when for treating grice diarrhoea is reduced, and improves therapeutic effect, reduce side effect.
Description
Technical field
The present invention relates to treating epidemic disease of domestic animals Prevention Technique field, in particular to a kind of scutelloside aluminium for treating grice diarrhoea is dry-mixed
Suspension and preparation method thereof.
Background technique
Grice diarrhoea is a kind of typical multifactor property disease under intensive pig production working condition.The disease is most tight at present
One of the piglet diseases group of weight, and cause the major reason of piglet death.According to relevant report, piglet accounts for piglet because of diarrhea death
The 39.8% of dead sum.In recent years, China's grice diarrhoea is very universal, 30kg piglet below, average of the whole year disease incidence
46.5%, the death rate 10.3%.In such as U.S. of the more developed country of pig breeding industry, the death rate about 15.5% before weaned piglet, Holland
11.5%~14.2%, grice diarrhoea ranks first in pig breeding industry harm, seriously threatens the sound development of pig breeding industry, causes to raise
Expect that rate of returns is lower, piglet survival ratio decline, slow growth, growth and development are stagnated, or even dead.
At present treatment the most common method of grice diarrhoea be using antibacterials, since the drug resistance of current bacterium is serious,
Cause therapeutic effect poor.Also the relevant technologies replace antibacterials using Chinese medicine, it, should for example, by using scutelloside aluminium dry suspensoid agent
Scutelloside aluminium dry suspensoid agent is prepared by Baical Skullcap root P.E (effective component extracted in radix scutellariae) and aluminium salt reaction, the radix scutellariae
The complicated component of extract, purity is low, has certain side effect to piglet.
Summary of the invention
The main object of the present invention is to propose a kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea,
It is intended to provide that a kind of pair of grice diarrhoea therapeutic effect be good, scutelloside aluminium dry suspensoid agents of Small side effects.
To achieve the above object, the present invention proposes a kind of scutelloside aluminium dry suspensoid agent for treating grice diarrhoea, with mass parts
Number meter includes following components:
Active constituent: 510~550 parts；
Filler: 435~485 parts；
Suspending agent: 5~15 parts；
Wherein, the active constituent is scutelloside and the scutelloside aluminum complex that aluminium salt is prepared into.
Preferably, the mass fraction of the active constituent is 520~540 parts, the mass fraction of the filler is 450~
470 parts, the suspending agent is 10~15 parts.
Preferably, the filler is one of mannitol, microcrystalline cellulose and lactose or a variety of.
Preferably, the suspending agent is one of xanthan gum, sodium alginate and sodium carboxymethylcellulose or a variety of.
Preferably, the suspending agent is xanthan gum, and the mass fraction of the xanthan gum is 10 parts.
Preferably, the partial size of the active constituent is 100~200 mesh；And/or
The partial size of the filler and the suspending agent is 100~200 mesh.
Preferably, the partial size of the active constituent is 200 mesh；And/or
The partial size of the filler and the suspending agent is 100 mesh.
To achieve the above object, the present invention also proposes a kind of preparation method of scutelloside aluminium dry suspensoid agent as described above,
The following steps are included:
By scutelloside aluminum complex grinding and sieving, active constituent is obtained；
Filler and suspending agent are distinguished into grinding and sieving, to deserved filler powder and suspending agent powder；
The active constituent and the filler powder and the suspending agent powder are mixed evenly, it is dry to obtain scutelloside aluminium
Suspension.
Preferably, the active constituent and the filler powder and the suspending agent powder are mixed evenly, obtain Huang
The step of a kind of reed mentioned in ancient books glycosides aluminium dry suspensoid agent, specifically:
The active constituent is uniformly mixed with the filler powder and the suspending agent powder according to equal increments method,
Obtain scutelloside aluminium dry suspensoid agent.
In technical solution provided by the invention, prepared scutelloside aluminium cooperation is reacted with aluminium salt using scutelloside raw material
Object is prepared by mixing into scutelloside aluminium dry suspensoid agent as active constituent, with filler and suspending agent, improves the dry suspensoid agent
The purity of middle scutelloside aluminum complex reduces the scutelloside aluminium dry suspensoid agent and uses agent when for treating grice diarrhoea
Amount, and improve therapeutic effect, reduce side effect.
Specific embodiment
It in order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below will be in the embodiment of the present invention
Technical solution be clearly and completely described.The person that is not specified actual conditions in embodiment, according to normal conditions or manufacturer builds
The condition of view carries out.Reagents or instruments used without specified manufacturer is the conventional production that can be obtained by commercially available purchase
Product.
The present invention proposes a kind of scutelloside aluminium dry suspensoid agent for treating grice diarrhoea, including with the following group in terms of mass fraction
Point: active constituent: 510~550 parts；Filler: 435~485 parts；Suspending agent: 5~15 parts；Wherein, the active constituent is Huang
The scutelloside aluminum complex that a kind of reed mentioned in ancient books glycosides and aluminium salt are prepared into.
Radix scutellariae is a kind of traditional Chinese medicine, is used as medicine with root, bitter, cold in nature, there is heat-clearing and damp-drying drug, purging fire for removing toxin, hemostasis, miscarriage prevention
And other effects, cure mainly warm heat disease, the infection of the upper respiratory tract, cough with lung heat, neonatal jaundice caused by dampness-heat, pneumonia, dysentery, hemoptysis, hot eyes, movement of the foetus not
The diseases such as peace, hypertension, carbuncle swells furuncle sore.The clinical antibiotic property of radix scutellariae is better than the coptis, and does not develop drug resistance.
Scutelloside is that a kind of flavone compound separated is extracted from the dry root of radix scutellariae, is faint yellow under room temperature
Powder, bitter, have significant bioactivity, have antibacterial, diuresis, anti-inflammatory, norcholesterol, antithrombus formation, alleviate asthma,
Purging fire for removing toxin, hemostasis, miscarriage prevention, antiallergic action and spasmolysis.Studies have shown that scutelloside antibacterial range is wider, especially to gold
Staphylococcus aureus, Pseudomonas aeruginosa effect are stronger, or even also have bacteriostasis to drug-resistant S. aureus.
When the active constituent of the existing drug using Baicalin metal complex as treatment grice diarrhoea, the scutelloside metal
Complex is prepared by Baical Skullcap root P.E and reacting metal salt, however the complicated component of the Baical Skullcap root P.E, radix scutellariae
Glycosides purity is low, when being used as the drug for the treatment of grice diarrhoea, has certain side effect to piglet.
Directly reacted using scutelloside raw material with aluminium salt in the present invention prepared scutelloside aluminum complex as it is active at
Point, it is prepared by mixing into scutelloside aluminium dry suspensoid agent with filler and suspending agent, scutelloside aluminium in the dry suspensoid agent is improved and matches
The purity for closing object, reduces dosage of scutelloside aluminium dry suspensoid agent when for treating grice diarrhoea, can be used for
Treatment is mainly due to grice diarrhoea caused by bacterium infection, and wean, turns group and stress wait grice diarrhoea caused by reasons, and
, few side effects significant to the therapeutic effect of grice diarrhoea, can be used as the drug of substitute antibiotics.It should be noted that with Huang
A kind of reed mentioned in ancient books glycosides and reacting metal salt preparation Baicalin metal complex belong to the prior art, and the invention reside in choose with the radix scutellariae of high-purity
Glycosides raw material reacts active constituent of the scutelloside aluminium of preparation as the dry suspensoid agent as reactant with aluminium salt, therefore, to Huang
A kind of reed mentioned in ancient books glycosides reacts the preparation method for preparing scutelloside aluminum complex with aluminium salt and process does not repeat them here.
As a kind of preferred embodiment provided by the invention, the mass fraction of the active constituent is 520~540 parts,
The mass fraction of the filler is 450~470 parts, and the suspending agent is 10~15 parts.
Dry suspensoid agent refers to insoluble drug and powder or shot-like particle is made in proper auxiliary materials, faces the used time and water is added to shake
Suspension is dispersed into for oral liquid preparation, the characteristics of the existing solid pharmaceutical preparation of dry suspensoid agent (particle), is such as convenient for carrying, transports
It is convenient, stability is good etc., and has the advantage of liquid preparation, conveniently take, be suitable for swallowing the patient having any problem, such as children, always
People etc..Ideal dry suspensoid agent gently shakes energy after should also settling slow, sedimentation in addition to should have validity and chemical stability
Redisperse, thus during the preparation process in addition to filler is added as carrier, it is also necessary to suspending agent is added.
In the present embodiment, the filler is one of mannitol, microcrystalline cellulose and lactose or a variety of, both can be with
It is any one in above-mentioned three kinds of substances, any two kinds or three kinds of mixture being also possible in above-mentioned three kinds of substances,
It can be used as the filler in the embodiment of the present invention.
The suspending agent is one of xanthan gum, sodium alginate and sodium carboxymethylcellulose or a variety of, either on
Any one in three kinds of substances is stated, any two kinds or three kinds of mixture being also possible in above-mentioned three kinds of substances,
It can satisfy phase using the sedimentation volume ratio as the suspending agent in the embodiment of the present invention, the prepared dry suspensoid agent
The requirement of pass standard.
It is highly preferred that the suspending agent is xanthan gum, and the mass fraction of the xanthan gum is 10 parts.Xanthan gum is selected to make
For the suspending agent, not only sedimentation volume ratio can satisfy the requirement of relevant criterion to the prepared dry suspensoid agent, but also have
There is good redispersibility energy.
Since the scutelloside aluminium dry suspensoid agent is in the use process for treating grice diarrhoea, need to make Piglet by Oral
Enter in vivo, in order to avoid the phenomenon that dysphagia occurs in piglet, the partial size of the scutelloside aluminium dry suspensoid agent be should not be too large, at this
The partial size in inventive embodiments being preferably the active constituent is 100~200 mesh；And/or the filler and the suspending agent
Partial size be 100~200 mesh, in this way, not only contributing to piglet can smoothly gulp down when taking the scutelloside aluminium dry suspensoid agent
Pharynx can also make the efficient mixing of scutelloside aluminium dry suspensoid agent supplementary material during the preparation process.
It is highly preferred that the partial size of the active constituent is 200 mesh；And/or the partial size of the filler and the suspending agent
For 100 mesh, the partial size of the active constituent is less than the partial size of the filler and the suspending agent, enables the active constituent
It enough spreads more evenly across in the filler and the suspending agent.
The present invention also proposes a kind of preparation method of the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as described above, packet
Include following steps:
Step S10, by scutelloside aluminum complex grinding and sieving, active constituent is obtained；
Step S20, filler and suspending agent are distinguished into grinding and sieving, to deserved filler powder and suspending agent powder；
Step S30, the active constituent and the filler powder and the suspending agent powder are mixed evenly, obtain Huang
A kind of reed mentioned in ancient books glycosides aluminium dry suspensoid agent.
Wherein, step S10 and step S20 can be step S10 preceding, and step S20 is rear；It is also possible to step S20 to exist
Before, step S10 is rear；It is also possible to separately carry out simultaneously, is not particularly limited herein.
Step S10 and step S20 in the specific implementation, can routinely be set using high speed disintegrator or mortar, mill etc.
It is standby to carry out, it will be illustrated for using Universalpulverizer below, the specific implementation method of step S10 and step S20 are as follows:
Scutelloside aluminum complex is smashed it through into 100~200 meshes, obtains active constituent；Filler and suspending agent are smashed it through respectively
100~200 meshes, to deserved filler powder and suspending agent powder.
In step slo, scutelloside aluminum complex is more preferably smashed it through into 200 meshes, obtains active constituent；In step
In S20, more preferably filler and suspending agent smash it through 100 meshes respectively, to deserved filler powder and suspending agent powder,
In this way, the partial size of the active constituent is less than the partial size of the filler and the suspending agent, enable the active constituent
It spreads more evenly across in the filler and the suspending agent.
Step S30 in the specific implementation, specifically: by the active constituent and the filler powder and the suspending agent
Powder is uniformly mixed according to equal increments method, obtains scutelloside aluminium dry suspensoid agent.In the present embodiment, i.e., are as follows: first take described help
Suspension and the active constituent and the filler with the quality such as the suspending agent, are placed in high-speed mixer and are uniformly mixed
Mixture is formed, then the active constituent and the filler with quality such as the mixtures are added thereto, is mixed again
Close uniformly, in this way, until the active constituent and the filler all addition finishes and after mixing, obtain the Huang
A kind of reed mentioned in ancient books glycosides aluminium dry suspensoid agent.
Technical solution of the present invention is described in further detail below in conjunction with specific embodiment, it should be understood that following real
It applies example to be only used to explain the present invention, be not intended to limit the present invention.
One, the preparation of scutelloside aluminium dry suspensoid agent
Embodiment 1
(1) raw material weighs: scutelloside aluminum complex 530g, xanthan gum 10g, lactose 460g；
(2) scutelloside aluminum complex the preparation of scutelloside aluminium dry suspensoid agent: is smashed it through into 200 mesh with Universalpulverizer
Sieve, obtains active constituent；Xanthan gum and lactose are smashed it through into 100 meshes with Universalpulverizer respectively, obtain xanthan gum powder and cream
Icing Sugar material；Active constituent is mixed into mixing according to equal increments method with xanthan gum powder and lactose powder, it is dry that scutelloside aluminium is made
Suspension.
Embodiment 2
(1) raw material weighs: scutelloside aluminum complex 520g, xanthan gum 15g, lactose 465g；
(2) scutelloside aluminum complex the preparation of scutelloside aluminium dry suspensoid agent: is smashed it through into 150 mesh with Universalpulverizer
Sieve, obtains active constituent；Xanthan gum and lactose are smashed it through into 100 meshes with Universalpulverizer respectively, obtain xanthan gum powder and cream
Icing Sugar material；Active constituent is mixed into mixing according to equal increments method with xanthan gum powder and lactose powder, it is dry that scutelloside aluminium is made
Suspension.
Embodiment 3
(1) raw material weighs: scutelloside aluminum complex 540g, xanthan gum 10g, lactose 450g；
(2) scutelloside aluminum complex the preparation of scutelloside aluminium dry suspensoid agent: is smashed it through into 100 mesh with Universalpulverizer
Sieve, obtains active constituent；Xanthan gum and lactose are smashed it through into 100 meshes with Universalpulverizer respectively, obtain xanthan gum powder and cream
Icing Sugar material；Active constituent is mixed into mixing according to equal increments method with xanthan gum powder and lactose powder, it is dry that scutelloside aluminium is made
Suspension.
Embodiment 4
(1) raw material weighs: scutelloside aluminum complex 525g, xanthan gum 15g, lactose 460g；
(2) scutelloside aluminum complex the preparation of scutelloside aluminium dry suspensoid agent: is smashed it through into 200 mesh with Universalpulverizer
Sieve, obtains active constituent；Xanthan gum and lactose are smashed it through into 150 meshes with Universalpulverizer respectively, obtain xanthan gum powder and cream
Icing Sugar material；Active constituent is mixed into mixing according to equal increments method with xanthan gum powder and lactose powder, it is dry that scutelloside aluminium is made
Suspension.
Embodiment 5
(1) raw material weighs: scutelloside aluminum complex 535g, xanthan gum 12g, lactose 453g；
(2) scutelloside aluminum complex the preparation of scutelloside aluminium dry suspensoid agent: is smashed it through into 200 mesh with Universalpulverizer
Sieve, obtains active constituent；Xanthan gum and lactose are smashed it through into 200 meshes with Universalpulverizer respectively, obtain xanthan gum powder and cream
Icing Sugar material；Active constituent is mixed into mixing according to equal increments method with xanthan gum powder and lactose powder, it is dry that scutelloside aluminium is made
Suspension.
Embodiment 6
(1) raw material weighs: scutelloside aluminum complex 510g, xanthan gum 5g, mannitol 485g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 7
(1) raw material weighs: scutelloside aluminum complex 550g, xanthan gum 10g, microcrystalline cellulose 440g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 8
(1) raw material weighs: scutelloside aluminum complex 510g, sodium alginate 5g, lactose 485g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 9
(1) raw material weighs: scutelloside aluminum complex 525g, sodium alginate 15g, lactose 460g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 10
(1) raw material weighs: scutelloside aluminum complex 510g, sodium alginate 10g, lactose 480g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 11
(1) raw material weighs: scutelloside aluminum complex 550g, sodium carboxymethylcellulose 5g, lactose 445g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 12
(1) raw material weighs: scutelloside aluminum complex 540g, sodium carboxymethylcellulose 10g, lactose 450g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Embodiment 13
(1) raw material weighs: scutelloside aluminum complex 525g, sodium carboxymethylcellulose 15g, lactose 460g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Comparative example 1
(1) raw material weighs: scutelloside aluminum complex 450g, xanthan gum 3g, lactose 547g；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
Comparative example 2
(1) raw material weighs: scutelloside aluminum complex 490g, xanthan gum 6g, lactose 500g, wherein the Huang in this comparative example
A kind of reed mentioned in ancient books glycosides aluminum complex is that the medical fluid after carrying out soak extraction by raw material of radix scutellariae reacts the product prepared with aluminium salt；
(2) the preparation method is the same as that of Example 1 for scutelloside aluminium dry suspensoid agent.
According to the regulation of " Republic of China Veterinary Pharmacopoeia " (version one in 2015) in relation to dry suspensoid agent sedimentation volume ratio
It is tested, as a result the sedimentation volume ratio of scutelloside aluminium dry suspensoid agent prepared by measurement embodiment 1 to embodiment 12 see the table below 1.
Quality evaluating method according to " Chinese veterinary pharmacopoeia " (version in 2015) about dry suspensoid agent, Huang prepared by measurement embodiment 1 to 12
The suspension performance of a kind of reed mentioned in ancient books glycosides aluminium dry suspensoid agent, the results are shown in Table 1.
The suspension performance of the scutelloside aluminium dry suspensoid agent of 1 embodiment and comparative example of table preparation
According in " Republic of China Veterinary Pharmacopoeia " (version one in 2015) annex about the related rule under suspension item
It is fixed, weight differential < 10%, loss on drying < 2%, determine dry suspensoid agent whether He Ge main indicator for sedimentation volume ratio not
Less than 0.90.By the data in table 1 it is found that the settling volume of scutelloside aluminium dry suspensoid agent prepared by the embodiment of the present invention 1 to 12
Than being respectively less than 0.90, meet regulation；Moreover, when select active constituent cross 200 meshes, using 10 parts of xanthan gum as suspending agent,
And suspending agent and filler, when sieving with 100 mesh sieve, the redispersibility of prepared scutelloside aluminium dry suspensoid agent is substantially better than other realities
Apply example.And for comparative example 1 and comparative example 2, sedimentation volume ratio is lower than embodiment 1 to embodiment 12.Two, scutelloside aluminium
Dry suspensoid agent is used to treat the clinical trial of grice diarrhoea
1, case diagnosis: with natural cases according to epidemiology, clinical symptoms, pathological change, Laboratory Diagnosed.Comprehensive point
Analysis, is made a definite diagnosis.
2, result judgement:
Cure: affected animal illness completely disappears after medication 3-4 times, and spirit, body temperature, appetite restore normal, and urine excrement is normal.
Effective: affected animal illness disappears substantially after medication 3-4 times, and spirit, body temperature, appetite make moderate progress, and urine excrement is normal.
Invalid: affected animal illness does not disappear after medication 4 times, and sb.'s illness took a turn for the worse or dead, and urine stool colour, character are abnormal.
Separately verify the scutelloside aluminium dry suspensoid agent pair that embodiment 1 is prepared to embodiment 13 and comparative example 1, comparative example 2
5 ages in days, 10 ages in days, 15 ages in days and wean one week grice diarrhoea clinical trial, including count scutelloside aluminium dry suspensoid agent pair
Effective percentage, cure rate and the side effect of piglet.
15 age in days diarrhea piglet of Application Example
5 age in days diarrhea piglets 300 are chosen, 20 are one group, are divided into 15 groups of (test group 1 to test group 13 and comparisons
Group 1 and contrast groups 2), administration mode are as follows: the scutelloside aluminium that Example 1 to embodiment 13 and comparative example 1 are prepared is dry-mixed
(embodiment 1 to the dry suspensoid agent that embodiment 13 is prepared respectively corresponds medicine-feeding test group 1 to test group 13, comparative example 1 to suspension
Contrast groups 1 are administered in the dry suspensoid agent of preparation), every 20g mono- is wrapped, and when use adds water to be mixed, and is made into the suspension (suspension of 100mL
The concentration of middle scutelloside aluminium dry suspensoid agent is 0.2g/mL), feeding 1 time daily is 5mL/ each (to be equivalent to feeding radix scutellariae every time
The dosage of glycosides aluminium dry suspensoid agent is 1g/)；The scutelloside aluminium dry suspensoid agent administration contrast groups 2 for taking comparative example 2 to be prepared, often
15g mono- is wrapped, and when use adds water to mix, and being made into the suspension of 50mL, (concentration of scutelloside aluminium suspension is 0.3g/ in suspension
ML), feeding 1 time daily, it is 5mL/ each (dosage for being equivalent to feeding scutelloside aluminium dry suspensoid agent every time is 1.5g/).It gives
After medicine 1 day, treatment results are observed.As a result as shown in table 2 below.
Efficacy result comparison in 2 Application Example 1 of table
2 10 age in days severe diarrhea piglet of Application Example
Choose 10 age in days severe diarrhea piglets 300,20 are one group, be divided into 15 groups (test group 1 to test group 13, with
And contrast groups 1 and contrast groups 2), administration mode are as follows: the scutelloside that Example 1 to embodiment 13 and comparative example 1 are prepared
Aluminium dry suspensoid agent (embodiment 1 to the dry suspensoid agent that embodiment 13 is prepared respectively corresponds medicine-feeding test group 1 to test group 13,
Contrast groups 1 are administered in dry suspensoid agent prepared by comparative example 1), every 20g mono- is wrapped, and when use adds water to be mixed, and is made into the suspension of 100mL
(concentration of scutelloside aluminium dry suspensoid agent is 0.2g/mL in suspension), feeding 2 times, 5mL/ each (to be equivalent to each feeding daily
The dosage for feeding scutelloside aluminium dry suspensoid agent is 1g/)；The scutelloside aluminium dry suspensoid agent administration comparison for taking comparative example 2 to be prepared
Group 2, every 15g mono- are wrapped, and when use adds water to mix, and being made into the suspension of 50mL, (concentration of scutelloside aluminium suspension is in suspension
0.3g/mL), feeding 2 times daily, 5mL/ each (dosage for being equivalent to feeding scutelloside aluminium dry suspensoid agent every time is 1.5g/
Head).After administration 2 days, treatment results are observed.Treatment results are as shown in table 3 below.
Efficacy result comparison in 3 Application Example 2 of table
3 15 age in days diarrhea piglet of Application Example
Choose 15 age in days diarrhea piglets 300,20 are one group, are divided into 15 groups of (test groups 1 to test group 13 and right
Than group 1 and contrast groups 2), administration mode are as follows: the scutelloside aluminium that Example 1 to embodiment 13 and comparative example 1 are prepared is dry
(embodiment 1 to the dry suspensoid agent that embodiment 13 is prepared respectively corresponds medicine-feeding test group 1 to test group 13, comparison to suspension
Contrast groups 1 are administered in dry suspensoid agent prepared by example 1), every 20g mono- is wrapped, and when use adds water to be mixed, and the suspension for being made into 100mL (is suspended
The concentration of scutelloside aluminium dry suspensoid agent is 0.2g/mL in liquid), feeding 1 time daily is 5mL/ each (it is yellow to be equivalent to feeding every time
The dosage of a kind of reed mentioned in ancient books glycosides aluminium dry suspensoid agent is 1g/)；The scutelloside aluminium dry suspensoid agent administration contrast groups 2 for taking comparative example 2 to be prepared,
Every 15g mono- is wrapped, and when use adds water to mix, and being made into the suspension of 50mL, (concentration of scutelloside aluminium suspension is 0.3g/ in suspension
ML), feeding 1 time daily, it is 5mL/ each (dosage for being equivalent to feeding scutelloside aluminium dry suspensoid agent every time is 1.5g/).It gives
After medicine 1 day, treatment results are observed.As a result as shown in table 4 below.
The efficacy result of 4 Application Example 3 of table compares
The diarrhea piglet of the wean of Application Example 4 after a week
Choose wean after a week diarrhea piglet 300,20 are one group, be divided into 15 groups (test group 1 to test group 13,
And contrast groups 1 and contrast groups 2), administration mode are as follows: the radix scutellariae that Example 1 to embodiment 13 and comparative example 1 are prepared
(embodiment 1 to the dry suspensoid agent that embodiment 13 is prepared respectively corresponds medicine-feeding test group 1 to test group to glycosides aluminium dry suspensoid agent
13, contrast groups 1 are administered in dry suspensoid agent prepared by comparative example 1), every 20g mono- is wrapped, and when use adds water to be mixed, and is made into the suspension of 100mL
Liquid (concentration of scutelloside aluminium dry suspensoid agent is 0.2g/mL in suspension), feeds 2 times (once in the morning and once at night), each 5mL/ daily
Head (dosage for being equivalent to feeding scutelloside aluminium dry suspensoid agent every time is 1g/)；The scutelloside aluminium for taking comparative example 2 to be prepared is dry
Suspensions administration contrast groups 2, every 15g mono- are wrapped, and when use adds water to mix, and are made into suspension (the scutelloside aluminium in suspension of 50mL
The concentration of suspension is 0.3g/mL), 2 times (once in the morning and once at night) is fed daily, it is 5mL/ each (to be equivalent to feeding radix scutellariae every time
The dosage of glycosides aluminium dry suspensoid agent is 1.5g/).After successive administration 3 days, treatment results are observed.As a result as shown in table 5 below.
The efficacy result of 5 Application Example 4 of table compares
It can be seen that from efficacy result of the table 2 into table 5 and be less than 510 parts compared to scutelloside aluminum complex additive amount
For comparative example 1, the average cure rate and average effectiveness level of test group 1-13 is apparently higher than contrast groups 1, illustrates implementation of the present invention
The scutelloside aluminium dry suspensoid agent that example 1 to 13 provides is more significant to the therapeutic effect of grice diarrhoea；Compared to Baical Skullcap root P.E with
For the scutelloside aluminum complex prepared in aluminium salt reaction is the comparative example 2 of active constituent, test group 1-13 is flat with contrast groups 2
Equal effective percentage is not much different, but the average cure rate of test group 1-13 is higher, moreover, the dry suspensoid agent in contrast groups 2 is being controlled
Used dosage is 1.5g/ head during treating grice diarrhoea, hence it is evident that higher than the 1g/ head in test group, and in test group 1-13
Apparent side effect is not occurred, illustrates that the scutelloside aluminium dry suspensoid agent that the embodiment of the present invention 1 to 13 provides is being used to treat
When grice diarrhoea, not only dosage is small, but also therapeutic effect is more significant, few side effects.
The above is only a preferred embodiment of the present invention, is not intended to limit the scope of the invention, for this field
For technical staff, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any
Modification, equivalent replacement, improvement etc. should all be included within the scope of the present invention.
Claims (9)
1. a kind of scutelloside aluminium dry suspensoid agent for treating grice diarrhoea, which is characterized in that including following components in terms of mass fraction:
Active constituent: 510~550 parts；
Filler: 435~485 parts；
Suspending agent: 5~15 parts；
Wherein, the active constituent is scutelloside and the scutelloside aluminum complex that aluminium salt is prepared into.
2. the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as described in claim 1, which is characterized in that the active constituent
Mass fraction be 520~540 parts, the mass fraction of the filler is 450~470 parts, and the suspending agent is 10~15 parts.
3. the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as described in claim 1, which is characterized in that the filler is
One of mannitol, microcrystalline cellulose and lactose are a variety of.
4. the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as described in claim 1, which is characterized in that the suspending agent is
One of xanthan gum, sodium alginate and sodium carboxymethylcellulose are a variety of.
5. the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as claimed in claim 4, which is characterized in that the suspending agent is
Xanthan gum, the mass fraction of the xanthan gum are 10 parts.
6. the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as described in claim 1, which is characterized in that the active constituent
Partial size be 100~200 mesh；And/or
The partial size of the filler and the suspending agent is 100~200 mesh.
7. the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as claimed in claim 6, which is characterized in that the active constituent
Partial size be 200 mesh；And/or
The partial size of the filler and the suspending agent is 100 mesh.
8. a kind of preparation side of the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as claimed in any one of claims 1 to 7
Method, which comprises the following steps:
By scutelloside aluminum complex grinding and sieving, active constituent is obtained；
Filler and suspending agent are distinguished into grinding and sieving, to deserved filler powder and suspending agent powder；
The active constituent and the filler powder and the suspending agent powder are mixed evenly, it is dry-mixed outstanding to obtain scutelloside aluminium
Agent.
9. the preparation method of the scutelloside aluminium dry suspensoid agent for the treatment of grice diarrhoea as claimed in claim 8, which is characterized in that will
The active constituent is mixed evenly with the filler powder and the suspending agent powder, obtains the step of scutelloside aluminium dry suspensoid agent
Suddenly, specifically:
The active constituent is uniformly mixed with the filler powder and the suspending agent powder according to equal increments method, is obtained
Scutelloside aluminium dry suspensoid agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811078651.7A CN109091462A (en) | 2018-09-14 | 2018-09-14 | A kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811078651.7A CN109091462A (en) | 2018-09-14 | 2018-09-14 | A kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109091462A true CN109091462A (en) | 2018-12-28 |
Family
ID=64866571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811078651.7A Withdrawn CN109091462A (en) | 2018-09-14 | 2018-09-14 | A kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109091462A (en) |
-
2018
- 2018-09-14 CN CN201811078651.7A patent/CN109091462A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026459T2 (en) | Simethicone-containing laxative | |
| CN106667915B (en) | It is a kind of for treating the scutelloside aluminium dry suspensoid agent of grice diarrhoea | |
| CN102470183A (en) | Pharmaceutical composition containing dimethicone/ simethicone | |
| JPS6023323A (en) | Medicinal composition | |
| CA2229658A1 (en) | Combination osmotic and bulk forming laxatives | |
| CN104906121B (en) | Pharmaceutical composition containing tylonolide | |
| CN102258614A (en) | Compound propolis composition for treating white diarrhea and chronic respiratory disease and preparation method thereof | |
| CN101856418B (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
| CN108272087A (en) | A kind of blood fat reducing food and preparation method thereof | |
| CN107281110B (en) | Tannic acid protein powder capable of being administrated by drinking water and preparation method thereof | |
| CN104922140B (en) | A kind of tylonolide composition and its application in treating or preventing fowl upper disease | |
| CN114272213A (en) | Florfenicol powder and preparation method thereof | |
| CN113841904A (en) | Preparation method and application of konjac gel powder | |
| CN109091462A (en) | A kind of scutelloside aluminium dry suspensoid agent and preparation method thereof for treating grice diarrhoea | |
| CN109125268A (en) | A kind of scutelloside copper dry suspensoid agent and preparation method thereof for treating grice diarrhoea | |
| CN111529608A (en) | Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof | |
| CN106668185A (en) | Pharmaceutical composition for preventing and treating cattle and sheep urinary stones | |
| CN108785325A (en) | A kind of scutelloside zinc dry suspensoid agent and preparation method thereof for treating grice diarrhoea | |
| CN105919960B (en) | A kind of roxithromycin dispersing tablet and preparation method thereof | |
| CN109125269A (en) | A kind of scutelloside copper pre-mixing agent and preparation method thereof for treating grice diarrhoea | |
| CN109091461A (en) | A kind of scutelloside aluminium powder agent and preparation method thereof for treating grice diarrhoea | |
| CN108938570A (en) | A kind of scutelloside aluminium pre-mixing agent and preparation method thereof for treating grice diarrhoea | |
| CN108888632A (en) | A kind of scutelloside copper powder agent and preparation method thereof for treating grice diarrhoea | |
| CN103536624B (en) | A kind of wettable three-ingredient white composition powder and preparation method thereof | |
| CN109091463A (en) | A kind of scutelloside zinc powder agent and preparation method thereof for treating grice diarrhoea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181228 |